| Market Cap | 3.50M | P/E | - | EPS this Y | 60.10% | Ern Qtrly Grth | - |
| Income | -102.84M | Forward P/E | -0.07 | EPS next Y | 10.90% | 50D Avg Chg | -86.00% |
| Sales | 818k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -93.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -98.00% |
| Recommedations | 3.00 | Quick Ratio | 0.32 | Shares Outstanding | 49.86M | 52W Low Chg | 71.00% |
| Insider Own | 6.72% | ROA | -106.07% | Shares Float | 34.41M | Beta | 2.87 |
| Inst Own | 55.21% | ROE | - | Shares Shorted/Prior | 2.07M/1.47M | Price | 0.07 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,756,632 | Target Price | 1.00 |
| Oper. Margin | -12,738.63% | Earnings Date | Mar 22 | Volume | 8,603,716 | Change | 0.00% |
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Burkhardt Glen | SVP of Human Resourc.. SVP of Human Resources | May 20 | Sell | 0.79 | 11,248 | 8,886 | 05/24/22 | |
| Hutson Nancy J | Director Director | Aug 18 | Buy | 3.08 | 3,000 | 9,240 | 4,000 | 05/20/22 |
| Burkhardt Glen | VP, Human Resources VP, Human Resources | Nov 19 | Sell | 2.37 | 5,766 | 13,665 | 11/23/21 | |
| Hutson Nancy J | Director Director | Nov 05 | Option | 2.85 | 33,760 | 96,216 | 33,760 | 11/08/21 |
| Burkhardt Glen | VP, Human Resources VP, Human Resources | May 24 | Sell | 3.29 | 3,811 | 12,538 | 05/24/21 | |
| Burkhardt Glen | VP, Human Resources VP, Human Resources | Nov 23 | Sell | 3.45 | 3,497 | 12,065 | 11/23/20 | |
| Arnold Susan Elizabeth | VP, Preclinical and.. VP, Preclinical and Chem | Oct 05 | Option | 1.15 | 10,846 | 12,473 | 13,152 | 10/05/20 |